Sepsis Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 4575
Published in Apr, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Sepsis Diagnostics Market by Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029

Overview

The global sepsis Diagnostics market, valued at US$566 million in 2022, is forecasted to grow at a robust CAGR of 7.0%, reaching US$634 million in 2023 and an impressive US$890 million by 2029. The market growth is driven ongoing transformation of the US & European health systems towards value-based care, recent advances in biomarker-based diagnostic methods, and technological innovations in molecular diagnostics. For example, at hospitals and emergency care centers, point-of-care sepsis diagnostic methods are being increasingly used for the early detection of multiple organ failures, HAIs, and chronic infections in critically ill patients. The continued market growth is expected to be driven by the continued digitalization and automation of diagnostic lab workflows, the integration of rapid test kits with routine hospital workflows, the enabling of real-time data management capabilities with EHRs, and the government's worldwide emphasis on reducing mortality rates and improving patient care. Some of the notable startups in this regard include Genemark Diagnostics, QuantuMDx, Seegene, iPath Diagnostics, and Tasso.

Attractive Opportunities in the Sepsis Diagnostics Market

APAC

Market growth in the Asia Pacific region can be attributed to growing prevalence of sepsis coupled with the rising geriatric population.

Growth in this market can be attributed to the higher incidence of sepsis, rise in the number of HAIs, and growth initiatives by governments and healthcare organizations to boost research activities for sepsis diagnosis.

Blood culture products is expected to be the fastest-growing segment for market players during the forecast period.

The North American sepsis diagnostics market is projected to reach USD 391.2 million by 2029 from USD 275 million in 2024 at a CAGR of 7.3% during the forecast period.

Market growth in North America can be attributed to the strong demand for and adoption of sepsis diagnostics in the US.

Global Sepsis Diagnostics Market Dynamics

Driver: Increasing hospital-acquired infection incidences

The main driving force for the growth of the sepsis diagnostics market is the rising incidence of Hospital-acquired infections (HAIs). Hospital-acquired infections (healthcare-associated infections) are nosocomially acquired infections that are not present or incubating at the time of admission to a hospital. Globally there is a rapid increase in HAIs, due to which in the coming years the demand for sepsis diagnostic products is also expected to rise. In the US, sepsis is the third most common cause of death in U.S. hospitals affecting 1.7 million people nationwide each year (Source: Centers for Disease Control and Prevention (CDC)).

Restraint: High costs of automated diagnostic devices

The material used in the development of diagnostic devices significantly contribute to the cost of the automated diagnostic devices. For instance, the price of the molecular diagnostic tests is USD 300–3,000 (and above), thus diagnostic devices are too expensive (with advanced materials) to be used on a regular basis (mainly in the developing markets). The price is very high compared to the cost of blood culture tests, priced as low as ~USD 28–35. Further, though in developed countries sepsis diagnosis is relatively common, automated diagnostic devices are still unaffordable in countries with a per capita government healthcare expenditure below USD 50. Government hospitals (especially in emerging nations) and academic research laboratories due to limited budgets, cannot afford such systems.

Opportunity: Rapid diagnostic/POC techniques development for early sepsis diagnosis

The product offering are being expanded by many sepsis diagnostic manufacturers in point of care (POC) technology for rapidly detecting the sepsis, reducing the overall turnaround time of diagnosis. Within three hours in septic shock, the risk of mortality increases by 35% with every one hour delay in antibiotic administration. Thus, increasing the need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis. Becton Dickinson and Company (US) manufacture blood culturing instruments like BACTEC FX, BACTEC Plus and BacT/Alert which are automated microbial detection systems offering a rapid diagnosis of sepsis in the minimum turnaround time.

Challenge: Dearth of skilled healthcare professionals

The shortage of skilled professionals is a major concern worldwide. Sepsis is a life-threatening condition that needs to be diagnosed and treated at the earliest with the help of skilled healthcare professionals. The lack of trained paramedics affects each phase of patient care— screening patients for the presence of sepsis and sepsis awareness. Only 50% of patients with severe sepsis transported by the EMS system have a paramedic.

Global Sepsis Diagnostics Market Ecosystem Analysis

Market Ecosystem Map: Electronic Warfare Market

By technology, the blood culture segment accounted for the largest share of sepsis diagnostics industry during the forecast period.

ased on the technology, the sepsis diagnostics is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Molecular diagnostics is further sub-segmented into PCR, microarray, peptide nucleic acid fluorescent in situ hybridization and DNA sequencing. The blood culture segment accounts for the largest share of the sepsis diagnostics market. The extensive use of blood culture methods for the diagnosis of sepsis and the low cost of microbiology techniques contribute to the large share.

By product, the blood culture media segment of sepsis diagnostics industry is expected to grow at the highest rate during the forecast period.

Based on the product, the sepsis diagnostics is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2024, the blood culture media segment is expected accounted for the largest share of market during the forecast period. The increase in the availability of blood culture media and growing utilization of blood culture media by hospitals & pathology laboratories for the diagnosis of sepsis has led to the growth of the segment.

North America Region Holds the Largest Share of the Sepsis Diagnostics Market.

On the other hand, the Asia Pacific market is estimated to register the highest growth rate during the forecast period. North America accounted for a share of 43.4% of the market, followed by Europe with a share of 30.7%.

Recent Developments of Sepsis Diagnostics Market industry

  • In April 2023, BioMérieux launched BIOFIRE FIREWORKS, an integrated software solution for BIOFIRE Systems optimizing laboratory services and supporting data-driven decisions.
  • In May 2023, Sysmex Corporation launched clinical flow cytometry system Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products in Japan.

Key Market Players

KEY PLAYERS IN THE Sepsis Diagnostics Market INCLUDE

  • bioMérieux (France)
  • Becton, Dickinson and Company (US),
  • Danaher Corporation (US)
  • T2 Biosystems (US)
  •  QuidelOrtho Corporation (US)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Thermo Fisher Scientific (US),
  • Abbott Laboratories (US)
  •  Immunexpress (Australia)
  • Axis-Shield Diagnostics (UK)

Want to explore hidden markets that can drive new revenue in Sepsis Diagnostics Market?

Scope of the Report

Report Attribute Details
Market Revenue Size in 2024 $634 million
Projected Revenue Size by 2029 $890 million
Industry Growth Rate Poised to grow at a CAGR of 7.0%
Market Driver Increasing hospital-acquired infection incidences
Market Opportunity Rapid diagnostic/POC techniques development for early sepsis diagnosis

 

Key Questions Addressed by the Report

What is the expected growth of the global sepsis diagnostics market between 2024 and 2029?
The global sepsis diagnostics market is projected to grow from USD 634 million in 2024 to USD 890 million by 2029, demonstrating a robust CAGR of 7.0%.
What are the main drivers of the sepsis diagnostics market?
Key drivers include the rising incidence of hospital-acquired infections (HAIs), increasing demand for rapid diagnostic tools, and technological innovations in molecular diagnostics, which are essential for detecting sepsis early and reducing mortality rates.
What are the major challenges facing the sepsis diagnostics market?
One of the key challenges is the high cost of automated diagnostic devices, which limits their adoption, especially in developing markets. The shortage of skilled healthcare professionals also hinders the timely diagnosis and treatment of sepsis.
Which technologies dominate the sepsis diagnostics market?
The blood culture technology segment accounts for the largest share of the sepsis diagnostics market. However, advancements in molecular diagnostics, including PCR and DNA sequencing, are rapidly gaining traction due to their speed and accuracy in detecting pathogens.
What role do point-of-care diagnostic tools play in the sepsis diagnostics market?
Point-of-care (POC) diagnostic tools are increasingly used in hospital emergency departments for rapid sepsis detection, helping reduce the turnaround time for diagnosis and ensuring timely treatment to prevent septic shock.
Which products are expected to drive the growth of the sepsis diagnostics market?
The blood culture media segment is projected to grow at the highest rate during the forecast period, supported by the widespread use of blood culture methods in hospitals and laboratories for sepsis diagnosis.
Which regions are expected to see the highest growth in the sepsis diagnostics market?
Recent developments include the acquisition of Abcam by Danaher Corporation, and bioMérieux receiving FDA CLIA waiver for the BIOFIRE SPOTFIRE Respiratory Panel Mini, showcasing innovation in rapid testing solutions.
What impact do hospital-acquired infections have on the sepsis diagnostics market?
Hospital-acquired infections (HAIs) are a significant driver of the sepsis diagnostics market. The increasing incidence of HAIs worldwide, particularly in hospitals and long-term care facilities, is boosting the demand for rapid diagnostic tools to manage and prevent sepsis effectively.
How do biomarkers contribute to the growth of the sepsis diagnostics market?
Biomarker-based diagnostic methods are gaining traction in the sepsis diagnostics market due to their ability to provide early detection of sepsis, thereby improving patient outcomes and reducing the risk of multi-organ failure and mortality.
What are the key opportunities in the sepsis diagnostics market?
Rapid diagnostic techniques, particularly point-of-care testing, present significant growth opportunities in the sepsis diagnostics market. These methods help reduce the delay in antibiotic therapy, critical in managing sepsis effectively, and are expected to see widespread adoption in hospitals and emergency care settings.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Sepsis Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
29
RESEARCH METHODOLOGY
34
EXECUTIVE SUMMARY
46
PREMIUM INSIGHTS
51
MARKET OVERVIEW
54
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - High incidence of sepsis
    - Rising incidence of HAIs
    - Growing funding for sepsis-related research
    RESTRAINTS
    - High cost of automated diagnostic devices
    OPPORTUNITIES
    - Development of rapid diagnostic/POC techniques for early sepsis diagnosis
    - Evolution of novel biomarkers for sepsis diagnosis
    - Growth opportunities in emerging economies
    CHALLENGES
    - Lack of awareness and limited protocols for sepsis diagnosis
    - Shortage of skilled healthcare professionals
  • 5.3 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY TRENDS
    - North America
    - Europe
    - Asia Pacific
    - Latin America
  • 5.4 REIMBURSEMENT SCENARIO
  • 5.5 VALUE CHAIN ANALYSIS
    RESEARCH & DEVELOPMENT
    PROCUREMENT AND PRODUCT DEVELOPMENT
    MARKETING, SALES, AND DISTRIBUTION
  • 5.6 SUPPLY CHAIN ANALYSIS
    PROMINENT COMPANIES
    SMALL & MEDIUM-SIZED ENTERPRISES
    END USERS
  • 5.7 ECOSYSTEM ANALYSIS/MARKET MAP
  • 5.8 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
  • 5.9 TRADE ANALYSIS
  • 5.10 PATENT ANALYSIS
  • 5.11 PRICING ANALYSIS
  • 5.12 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Biomarkers
    - Microfluidics
    COMPLIMENTARY TECHNOLOGIES
    - Genomics and Transcriptomics
    - Machine Learning and Artificial Intelligence (AI)
    ADJACENT TECHNOLOGIES
    - Nanotechnology Sensors
    - Medical Imaging
    - Digital Health Solutions
  • 5.13 KEY CONFERENCES AND EVENTS IN 2023–2024
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 5.15 SEPSIS DIAGNOSTICS MARKET: RECESSION IMPACT
  • 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS
    KEY BUYING CRITERIA
  • 5.17 UNMET NEEDS AND KEY PAIN POINTS
  • 5.18 INVESTMENT SCENARIO
SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY
83
  • 6.1 INTRODUCTION
  • 6.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
    MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS
  • 6.3 IMMUNOASSAYS
    RISING PRODUCT DEVELOPMENT BY MAJOR PLAYERS TO SUPPORT MARKET GROWTH
  • 6.4 MOLECULAR DIAGNOSTICS
    POLYMERASE CHAIN REACTION
    - Quick turnaround time and technological advancements to propel market
    MICROARRAYS
    - Simultaneous analysis capabilities & accuracy to boost adoption
    PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION
    - Enables rapid diagnosis of bloodstream infections
    DNA SEQUENCING
    - Shortens time for sepsis diagnosis
  • 6.5 FLOW CYTOMETRY
    LACK OF STANDARDIZED PROTOCOLS—KEY FACTOR RESTRAINING MARKET GROWTH
  • 6.6 MICROFLUIDICS
    RISING ADOPTION OF ADVANCED AND RAPID TESTING TO DRIVE GROWTH
  • 6.7 BIOMARKERS
    RESEARCH & DEVELOPMENT FOR DISCOVERY OF NOVEL BIOMARKERS TO DRIVE GROWTH
SEPSIS DIAGNOSTICS MARKET, BY PRODUCT
105
  • 7.1 INTRODUCTION
  • 7.2 BLOOD CULTURE MEDIA
    RISE IN BLOODSTREAM INFECTIONS TO DRIVE GROWTH
  • 7.3 ASSAYS & REAGENT KITS
    ASSAYS BETTER ENABLE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS
  • 7.4 INSTRUMENTS
    INCREASING INCLINATION TOWARD RAPID DIAGNOSTIC SYSTEMS TO DRIVE MARKET
  • 7.5 SOFTWARE
    INCREASING USE OF AUTOMATED INSTRUMENTS TO DRIVE DEMAND FOR SOFTWARE
SEPSIS DIAGNOSTICS MARKET, BY METHOD
111
  • 8.1 INTRODUCTION
  • 8.2 CONVENTIONAL DIAGNOSTICS
    EASE OF USE AND LOW COST TO PROPEL MARKET GROWTH
  • 8.3 AUTOMATED DIAGNOSTICS
    ACCURACY AND QUICK TURNAROUND TIME TO DRIVE ADOPTION
SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE
115
  • 9.1 INTRODUCTION
  • 9.2 BACTERIAL SEPSIS
    GRAM-NEGATIVE BACTERIAL SEPSIS
    - Increasing demand for sepsis diagnostic tests to drive market
    GRAM-POSITIVE BACTERIAL SEPSIS
    - Increasing incidence of gram-positive nosocomial infections to propel market
  • 9.3 FUNGAL SEPSIS
    RISING INCIDENCE OF FUNGAL INFECTIONS TO PROPEL MARKET
  • 9.4 OTHER PATHOGEN TYPES
SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE
121
  • 10.1 INTRODUCTION
  • 10.2 LABORATORY TESTS
    MOST COMMON AND PREFERRED MODE OF TESTING
  • 10.3 POINT-OF-CARE TESTS
    INCREASING DEVELOPMENT OF NOVEL POC DIAGNOSTICS TO SUPPORT MARKET GROWTH
SEPSIS DIAGNOSTICS MARKET, BY END USER
125
  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS AND SPECIALTY CLINICS
    INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO DRIVE MARKET
  • 11.3 PATHOLOGY AND REFERENCE LABORATORIES
    INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES
  • 11.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
    GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION TO DRIVE GROWTH
SEPSIS DIAGNOSTICS MARKET, BY REGION
130
  • 12.1 INTRODUCTION
  • 12.2 NUMBER OF SEPSIS TEST PERFORMED, BY COUNTRY (2023)
  • 12.3 NORTH AMERICA
  • 12.4 RECESSION IMPACT ON NORTH AMERICAN SEPSIS DIAGNOSTICS MARKET
    US
    - Rising incidence of HAIs to drive demand
    CANADA
    - Growing availability of sepsis diagnostic products to support market growth
  • 12.5 EUROPE
    RECESSION IMPACT ON EUROPEAN SEPSIS DIAGNOSTICS MARKET
    GERMANY
    - Adoption of technologically advanced diagnostic products to drive market
    UK
    - Stringent government regulations to drive market growth
    FRANCE
    - High incidence of sepsis to propel growth
    ITALY
    - Supportive government initiatives for raising awareness on sepsis to drive market
    SPAIN
    - Rising awareness for early diagnosis of propel market
    REST OF EUROPE
  • 12.6 ASIA PACIFIC
    RECESSION IMPACT ON ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET
    JAPAN
    - Rising incidence of pneumonia and infectious diseases to support market growth
    CHINA
    - Healthcare infrastructure improvements to support market growth
    INDIA
    - Increasing patient population and rising number of surgical procedures to drive market
    AUSTRALIA
    - Rapid growth in sepsis treatment procedures to propel market
    SOUTH KOREA
    - Rising healthcare spending to support market growth
    REST OF ASIA PACIFIC
  • 12.7 LATIN AMERICA
    RECESSION IMPACT ON LATIN AMERICAN SEPSIS DIAGNOSTICS MARKET
    BRAZIL
    - Investments by leading sepsis diagnostic manufacturers to support market growth
    MEXICO
    - Rising medical tourism to drive market
    REST OF LATIN AMERICA
  • 12.8 MIDDLE EAST & AFRICA
    HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS TO PROPEL MARKET
    RECESSION IMPACT ON MIDDLE EAST & AFRICAN SEPSIS DIAGNOSTICS MARKET
    GCC COUNTRIES
    - Developments in healthcare infrastructure to drive market
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
179
  • 13.1 INTRODUCTION
  • 13.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
  • 13.3 REVENUE SHARE ANALYSIS
  • 13.4 MARKET SHARE ANALYSIS
    SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
    BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
    IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023
    MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
    BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • 13.5 COMPANY EVALUATION MATRIX (2023)
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT
  • 13.6 STARTUP/SME EVALUATION MATRIX (2023)
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING
  • 13.7 VALUATION AND FINANCIAL METRICS OF SEPSIS DIAGNOSTIC VENDORS
  • 13.8 PRODUCT/BRAND COMPARATIVE ANALYSIS
    BIOMÉRIEUX
    BECTON, DICKINSON AND COMPANY
    F. HOFFMANN-LA ROCHE LTD.
    DANAHER CORPORATION
    QIAGEN N.V.
  • 13.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
201
  • 14.1 KEY PLAYERS
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    T2 BIOSYSTEMS, INC.
    - Business overview
    - Products offered
    - Recent developments
    DIASORIN S.P.A.
    - Business overview
    - Products offered
    - Recent developments
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products Offered
    - Recent developments
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    BRUKER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    QUIDELORTHO CORPORATION
    - Business overview
    - Products offered
    SYSMEX CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    ABBOTT LABORATORIES
    - Business overview
    - Products offered
    SIEMENS HEALTHINEERS
    - Business overview
    - Products offered
    - Recent developments
    QIAGEN N.V.
    - Business overview
    - Products offered
    - Recent developments
    SEEGENE, INC.
    - Business overview
    - Products offered
    PHC HOLDINGS CORPORATION
    - Business overview
    - Products offered
    - Recent developments
  • 14.2 OTHER PLAYERS
    MCKESSON CORPORATION
    EKF DIAGNOSTICS HOLDINGS PLC
    RESPONSE BIOMEDICAL CORP.
    ALIFAX S.R.L.
    BODITECH MED INC.
    ADVANDX
    IMMUNEXPRESS INC.
    AXIS-SHIELD DIAGNOSTICS
    FUJIREBIO
    SEKISUI DIAGNOSTICS
    CURETIS GMBH
    NANOMIX INC.
    QVELLA CORPORATION
    MOLZYM GMBH & CO. KG
    CYTOVALE, INC.
APPENDIX
258
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
  • TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
  • TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
  • TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
  • TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS
  • TABLE 7 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS
  • TABLE 8 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 9 IMPORT DATA FOR BLOOD CULTURE MEDIA (HS CODE 3821), BY COUNTRY, 2018–2022 (USD)
  • TABLE 10 EXPORT DATA FOR BLOOD CULTURE MEDIA (HS CODE 3821), BY COUNTRY, 2018–2022 (USD)
  • TABLE 11 AVERAGE SELLING PRICE TREND OF MAJOR SEPSIS DIAGNOSTICS CONSUMABLES, BY REGION, 2023 (USD)
  • TABLE 12 AVERAGE SELLING PRICE TREND OF MAJOR SEPSIS DIAGNOSTICS INSTRUMENTS, BY REGION, 2023 (USD)
  • TABLE 13 AVERAGE SELLING PRICE TREND OF MAJOR SEPSIS DIAGNOSTICS CONSUMABLES, BY KEY PLAYER, 2023 (USD)
  • TABLE 14 AVERAGE SELLING PRICE TREND OF MAJOR SEPSIS DIAGNOSTICS INSTRUMENTS, BY KEY PLAYER, 2023 (USD)
  • TABLE 15 AVERAGE SELLING PRICE TREND OF MAJOR SEPSIS DIAGNOSTICS PRODUCTS, BY REGION, 2021–2023
  • TABLE 16 SEPSIS DIAGNOSTICS: LIST OF MAJOR CONFERENCES & EVENTS
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%)
  • TABLE 18 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
  • TABLE 19 SEPSIS DIAGNOSTICS MARKET: UNMET CUSTOMER NEEDS AND KEY PAIN POINTS
  • TABLE 20 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 21 BLOOD CULTURE MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 22 BLOOD CULTURE MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 23 BLOOD CULTURE MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 24 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 25 BLOOD CULTURE MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 26 BLOOD CULTURE MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 27 BLOOD CULTURE MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 28 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 29 IMMUNOASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 30 IMMUNOASSAYS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 31 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 32 IMMUNOASSAYS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 33 IMMUNOASSAYS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 34 IMMUNOASSAYS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 35 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 36 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 37 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 38 MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 39 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 40 MOLECULAR DIAGNOSTICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 41 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 42 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 43 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 44 MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 45 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 46 DNA SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 47 FLOW CYTOMETRY MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 48 FLOW CYTOMETRY MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 49 FLOW CYTOMETRY MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 50 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 51 FLOW CYTOMETRY MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 52 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 53 FLOW CYTOMETRY MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 54 MICROFLUIDICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 55 MICROFLUIDICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 56 MICROFLUIDICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 57 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 58 MICROFLUIDICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 59 MICROFLUIDICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 60 MICROFLUIDICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 61 BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 62 BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 63 BIOMARKERS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 64 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 65 BIOMARKERS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 66 BIOMARKERS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 67 BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 68 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 69 SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 70 SEPSIS DIAGNOSTIC ASSAYS & REAGENT KITS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 71 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 72 SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 73 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 74 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 75 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 76 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 77 BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 78 BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULTS
  • TABLE 80 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 81 GRAM-POSITIVE BACTERIAL CAUSES IN ADULTS
  • TABLE 82 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 83 FUNGAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 84 OTHER PATHOGEN TYPES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 85 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 86 LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 87 POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 88 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 89 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 90 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY AND REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 91 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 92 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 101 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 102 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 103 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 104 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 105 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 108 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 109 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 112 EUROPE: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 113 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 114 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 115 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 116 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 117 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 118 UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 119 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 120 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 121 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 122 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 123 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 124 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 125 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 126 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 129 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 130 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 134 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 136 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 137 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 138 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 139 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 140 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 141 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 142 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 143 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 144 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 145 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 146 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 147 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 150 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 151 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 152 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 153 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 154 LATIN AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 155 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 156 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 157 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 158 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 159 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 160 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 161 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 162 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 171 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 173 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 175 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 176 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 177 SEPSIS DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
  • TABLE 178 SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 179 SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 180 SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT
  • TABLE 181 SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 182 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 183 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MARCH 2024
  • TABLE 184 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2019–MARCH 2024
  • TABLE 185 SEPSIS DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2019–MARCH 2024
  • TABLE 186 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 187 BIOMÉRIEUX: PRODUCTS OFFERED
  • TABLE 188 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS
  • TABLE 189 BIOMÉRIEUX: DEALS
  • TABLE 190 BIOMÉRIEUX: OTHER DEVELOPMENTS
  • TABLE 191 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 192 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 193 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS
  • TABLE 194 BECTON, DICKINSON AND COMPANY: EXPANSIONS
  • TABLE 195 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 196 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 197 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS
  • TABLE 198 DANAHER CORPORATION: DEALS
  • TABLE 199 T2 BIOSYSTEMS INC.: COMPANY OVERVIEW
  • TABLE 200 T2 BIOSYSTEMS, INC.: PRODUCTS OFFERED
  • TABLE 201 T2 BIOSYSTEMS, INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 202 T2 BIOSYSTEMS, INC.: DEALS
  • TABLE 203 T2 BIOSYSTEMS, INC.: EXPANSIONS
  • TABLE 204 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 205 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 206 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 207 DIASORIN S.P.A.: DEALS
  • TABLE 208 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 209 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 210 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 211 F. HOFFMANN-LA ROCHE LTD.: DEALS
  • TABLE 212 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 213 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 214 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 215 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS
  • TABLE 216 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS
  • TABLE 217 BRUKER CORPORATION: COMPANY OVERVIEW
  • TABLE 218 BRUKER CORPORATION: PRODUCTS OFFERED
  • TABLE 219 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS
  • TABLE 220 BRUKER CORPORATION: DEALS
  • TABLE 221 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 222 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 223 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 224 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 225 SYSMEX CORPORATION: PRODUCT LAUNCHES & APPROVALS
  • TABLE 226 SYSMEX CORPORATION: OTHER DEVELOPMENTS
  • TABLE 227 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 228 ABBOTT LABORATORIES: PRODUCTS OFFERED
  • TABLE 229 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
  • TABLE 230 SIEMENS HEALTHINEERS: PRODUCTS OFFERED
  • TABLE 231 SIEMENS HEALTHINEERS: PRODUCT APPROVALS
  • TABLE 232 SIEMENS HEALTHINEERS: DEALS
  • TABLE 233 SIEMENS HEALTHINEERS: EXPANSIONS
  • TABLE 234 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 235 QIAGEN N.V.: PRODUCTS OFFERED
  • TABLE 236 QIAGEN N.V.: DEALS
  • TABLE 237 QIAGEN N.V.: EXPANSIONS
  • TABLE 238 SEEGENE, INC.: COMPANY OVERVIEW
  • TABLE 239 SEEGENE, INC.: PRODUCTS OFFERED
  • TABLE 240 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW
  • TABLE 241 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 242 PHC HOLDINGS CORPORATION: DEALS
  • TABLE 243 MCKESSON CORPORATION: COMPANY OVERVIEW
  • TABLE 244 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 245 RESPONSE BIOMEDICAL CORP.: COMPANY OVERVIEW
  • TABLE 246 ALIFAX S.R.L.: COMPANY OVERVIEW
  • TABLE 247 BODITECH MED INC.: COMPANY OVERVIEW
  • TABLE 248 ADVANDX: COMPANY OVERVIEW
  • TABLE 249 IMMUNEXPRESS INC.: COMPANY OVERVIEW
  • TABLE 250 AXIS-SHIELD DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 251 FUJIREBIO: COMPANY OVERVIEW
  • TABLE 252 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 253 CURETIS GMBH: COMPANY OVERVIEW
  • TABLE 254 NANOMIX INC.: COMPANY OVERVIEW
  • TABLE 255 QVELLA CORPORATION: COMPANY OVERVIEW
  • TABLE 256 MOLZYM GMBH & CO. KG: COMPANY OVERVIEW
  • TABLE 257 CYTOVALE, INC.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY
  • FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: SEPSIS DIAGNOSTICS MARKET
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 10 SEPSIS DIAGNOSTICS MARKET SHARE, BY METHOD, 2024 VS. 2029
  • FIGURE 11 SEPSIS DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2024 VS. 2029
  • FIGURE 12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 SEPSIS DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029
  • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF SEPSIS DIAGNOSTICS MARKET
  • FIGURE 15 HIGH INCIDENCE OF SEPSIS TO DRIVE MARKET
  • FIGURE 16 BLOOD CULTURE MEDIA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023
  • FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE SEPSIS DIAGNOSTICS MARKET DURING FORECAST PERIOD
  • FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 20 VALUE CHAIN ANALYSIS
  • FIGURE 21 SUPPLY CHAIN ANALYSIS
  • FIGURE 22 MARKET MAP
  • FIGURE 23 PATENT ANALYSIS
  • FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 26 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS
  • FIGURE 27 NUMBER OF DEALS & FUNDINGS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
  • FIGURE 28 NUMBER OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
  • FIGURE 29 VALUE OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
  • FIGURE 30 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 31 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 32 SEPSIS DIAGNOSTICS MARKET: STRATEGIES ADOPTED
  • FIGURE 33 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022 (USD MILLION)
  • FIGURE 34 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 35 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 36 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 37 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 38 BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 39 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX, 2023
  • FIGURE 40 SEPSIS DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 41 SEPSIS DIAGNOSTICS MARKET: STARTUP/SME EVALUATION MATRIX, 2023
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL (2023)
  • FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2022)
  • FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
  • FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 48 T2 BIOSYSTEMS INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
  • FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 52 BRUKER CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 54 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 55 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 56 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
  • FIGURE 57 QIAGEN N.V.: COMPANY SNAPSHOT (2022)

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the sepsis diagnostics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the sepsis diagnostics market. The primary sources from the demand side include OEMs, private and contract testing organizations and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Sepsis Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation Methodology

In this report, the global sepsis diagnostics market size was arrived at by using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the sepsis diagnostics products business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

Approach 1: Procedure-based estimation approach

To calculate the global market value, installation/volume consumption of sepsis diagnostic products were calculated. This process involved the following steps:

  • Finding the total number of hospitalization at the regional and/or country-level
  • The average number of sepsis cases at the regional and/or country level
  • The average number of sepsis diagnostics tests performed per patient at the regional and/or country-level
  • The average selling price of each product type for a given year was triangulated to arrive at the market value data at the regional and/or country-level

Sepsis Diagnostics Market Size Estimation

Approach 2: End user-based market estimation

During preliminary secondary research, the total sales revenue of sepsis diagnostics was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:

  • Generating a list of major customer facilities across each region and country
  • Identifying the average number of sepsis diagnostics product supplies used by major customer facilities across each product type at the regional/country level, annually
  • Identifying the percentage contribution of major customer facilities to the overall sepsis diagnostics expenditure and usage at the regional/country level, annually
  • Extrapolating the annual usage patterns for various products across major customer facilities to estimate the size of each product segment at the regional/country level, annually

Sepsis Diagnostics Market Size Estimation

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global sepsis diagnostics market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the sepsis diagnostics market was validated using both top-down and bottom-up approaches.

Market Definition

Sepsis is a life-threatening condition caused by pathogen infection. It develops when chemicals released into the bloodstream to fight the infection trigger inflammatory responses throughout the body. This is a three-stage syndrome—from sepsis to severe sepsis and septic shock. Septic shock is the last stage that results in extremely low blood pressure and a lack of response to normal fluid replacement. Inflammation leads to multi-organ failure; progress to septic shock could lead to death.

Key Market Stakeholders

  • Sepsis diagnostics reagents, instruments, blood culture media manufacturers
  • Research & academic laboratories
  • Healthcare service providers (including hospitals, reference labs, diagnostic centers, and specialty clinics)
  • Market research and consulting firms
  • Medical device suppliers, distributors, channel partners, and third-party suppliers
  • Business research and consulting service providers
  • Venture capitalists and other government funding organizations

Objectives of the Study

  • To define, describe, and forecast the sepsis diagnostics market on the basis of on technology, product, method, pathogen type, test type, end user and region.
  • To provide detailed information regarding the major factors influencing the growth potential of the global sepsis diagnostics market (drivers, restraints, opportunities, challenges, and trends).
  • To analyze the micro markets with respect to individual growth trends, future prospects, and contributions to the global sepsis diagnostics market.
  • To analyze key growth opportunities in the global sepsis diagnostics market for key stakeholders and provide details of the competitive landscape for market leaders.
  • To forecast the size of market segments and/or subsegments with respect to five major regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa (GCC Countries and Rest of MEA).
  • To profile the key players in the global sepsis diagnostics market and comprehensively analyze their market shares and core competencies.
  • To track and analyze the competitive developments undertaken in the global sepsis diagnostics market, such as agreements, expansions, and & acquisitions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global sepsis diagnostics market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

Company Information

  • Detailed analysis and profiling of additional market players (up to 15)

Geographic Analysis

  • Further breakdown of the Rest of Europe's sepsis diagnostics market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal among other
  • Further breakdown of the Rest of Asia Pacific sepsis diagnostics market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Rest of the Latin America sepsis diagnostics market into Argentina, Chile, Peru, and Colombia, among other

Previous Versions of this Report

Sepsis Diagnostics Market by Technology (Microbiology, PCR, Sequencing, Biomarkers), Product (Reagents, Assay, Instruments, Software), Test Type (Lab, POC), Pathogen (Bacterial, Viral, Fungal), End User (Hospital, Pathology Lab) - Global Forecast to 2026

Report Code MD 4575
Published in Feb, 2022, By MarketsandMarkets™

Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025

Report Code MD 4575
Published in May, 2020, By MarketsandMarkets™

Sepsis Diagnostics Market by Technology (Microbiology, Molecular Diagnostic, Immunoassay, Biomarkers), Product (Blood Culture Media, Instruments), Method (Automated), Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End-User - Global Forecast to 2023

Report Code MD 4575
Published in Apr, 2018, By MarketsandMarkets™

Sepsis Diagnostics Market by Technology (Microbiology, Molecular Diagnostic, Immunoassay, Biomarkers), Product (Blood Culture Media, Instruments), Method (Automated), Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End-User - Global Forecast to 2023

Report Code MD 4575
Published in Sep, 2016, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Sepsis Diagnostics Market

catherine

May, 2020

Have you not heard of T2 Biosystems rapid diagnostics direct from blood? Much faster than blood cultures, which is vital considering how quickly sepsis kills. FDA and CMS labeled it "breakthrough technology" and CMS subsidizes the test at 65, $97..

Barbara

Mar, 2022

What are the after-effects of the COVID19 on the Global Sepsis Diagnostics Industry?.

Susan

Mar, 2022

What are the upcoming trends in the Global Sepsis Diagnostics Industry?.

DMCA.com Protection Status